Evidence map›Paper›PMID 32191434›Full record

ArticleACS chemical biology2020

Bisubstrate-Type Chemical Probes Identify GRP94 as a Potential Target of Cytosine-Containing Adenosine Analogs.

Dany Pechalrieu, Fanny Assemat, Ludovic Halby, Marlene Marcellin, Pengrong Yan, Karima Chaoui, Sahil Sharma, Gabriela Chiosis, Odile Burlet-Schiltz, Paola B Arimondo and 1 more

Open access · greenAbstract read
In one paragraph

Article in ACS chemical biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Dany PechalrieuETaC, CNRS FRE3600, Centre de Recherche et Développement Pierre Fabre, Toulouse, France.
Fanny AssematETaC, CNRS FRE3600, Centre de Recherche et Développement Pierre Fabre, Toulouse, France.
Ludovic HalbyETaC, CNRS FRE3600, Centre de Recherche et Développement Pierre Fabre, Toulouse, France.
Marlene MarcellinInstitut de Pharmacologie et de Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France.
Pengrong YanProgram in Chemical Biology, Memorial Sloan Kettering Cancer Center, New York, New York, United States.
Karima ChaouiInstitut de Pharmacologie et de Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France.
Sahil SharmaProgram in Chemical Biology, Memorial Sloan Kettering Cancer Center, New York, New York, United States.
Gabriela ChiosisProgram in Chemical Biology, Memorial Sloan Kettering Cancer Center, New York, New York, United States.
Odile Burlet-SchiltzInstitut de Pharmacologie et de Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France.
Paola B ArimondoETaC, CNRS FRE3600, Centre de Recherche et Développement Pierre Fabre, Toulouse, France.ORCID 0000-0001-5175-4396
Marie LopezETaC, CNRS FRE3600, Centre de Recherche et Développement Pierre Fabre, Toulouse, France.
Centre National de la Recherche Scientifique · FRMemorial Sloan Kettering Cancer Center · USÉcole Nationale Supérieure de Chimie de Montpellier · FR

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Project 3: Structural Basis for grp94 Drug Development and Chaperone FunctionP01CA186866 · NCI · OHIO STATE UNIVERSITY · PI GEWIRTH, DANIEL T · 2015 to 2019
$6.7M
NCI NIH HHS P01 CA186866NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

We synthesized affinity-based chemical probes of cytosine-adenosine bisubstrate analogs and identified several potential targets by proteomic analysis. The validation of the proteomic analysis identified the chemical probe as a specific inhibitor of glucose-regulated protein 94 (GRP94), a potential drug target for several types of cancers. Therefore, as a result of the use of bisubstrate-type chemical probes and a chemical-biology methodology, this work opens the way to the development of a new family of GRP94 inhibitors that could potentially be of therapeutic interest.

Indexed as

AdenosineAffinity LabelsCell Line, TumorClick ChemistryCytosineHumansMembrane GlycoproteinsProteomeProteomicsUltraviolet RaysAdenosineAffinity LabelsCytosineendoplasminMembrane GlycoproteinsProteome

Identifiers

PMID32191434
PMCPMC7336334
OpenAlexW3011946269

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.